Your browser doesn't support javascript.
loading
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Chen, E X; Hotte, S; Hirte, H; Siu, L L; Lyons, J; Squires, M; Lovell, S; Turner, S; McIntosh, L; Seymour, L.
Afiliação
  • Chen EX; Princess Margaret Cancer Centre, University Health Network, Room 5-719, 610 University Avenue, Toronto, Ontario, Canada.
  • Hotte S; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Hirte H; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Siu LL; Princess Margaret Cancer Centre, University Health Network, Room 5-719, 610 University Avenue, Toronto, Ontario, Canada.
  • Lyons J; Astex Pharmaceutics, Cambridge, UK.
  • Squires M; Astex Pharmaceutics, Cambridge, UK.
  • Lovell S; Princess Margaret Cancer Centre, University Health Network, Room 5-719, 610 University Avenue, Toronto, Ontario, Canada.
  • Turner S; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • McIntosh L; NCIC Clinical Trials Group, Kingston, Ontario, Canada.
  • Seymour L; NCIC Clinical Trials Group, Kingston, Ontario, Canada.
Br J Cancer ; 111(12): 2262-7, 2014 Dec 09.
Article em En | MEDLINE | ID: mdl-25393368
BACKGROUND: AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs). It shows encouraging anti-cancer activity against multiple cell lines and in tumour xenografts. This phase I study was conducted to evaluate the safety and tolerability of AT7519 given as 1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks. METHODS: Patients with advanced refractory solid tumours or non-Hodgkin's lymphoma were enroled. Dose escalation occurred in a 3+3 manner based on toxicity assessment. Pharmacokinetic samples were collected after first AT7519 infusion, whereas pharmacodynamics (PD) samples were obtained in selected patients. RESULTS: Thirty-four patients were enroled, and 32 received study treatments over 4 dose levels. Dose-limiting toxicities included mucositis, febrile neutropenia, rash, fatigue and hypokalemia. The recommended phase II dose (RP2D) was 27.0 mg m(-2). Ten of 19 patients evaluable for efficacy had stable disease as the best response (median duration: 3.3 months; range: 2.5 to 11.1 months). There was no clinically significant QTc prolongation. There was an apparent dose proportional increase in AT7519 exposure. The PD studies showed reduction in markers of CDK activity in selected patients' skin biopsies post treatment. CONCLUSIONS: AT7519, when administered as an intravenous infusion on days 1, 4, 8 and 11, was well tolerated. The RP2D is 27.0 mg m(-2). At this dose level, plasma AT7519 concentrations were above the biologically active concentrations, and preliminary anti-cancer activity was observed in patients. This dosing schedule is being further evaluated in multiple phase II studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Pirazóis / Quinases Ciclina-Dependentes / Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Pirazóis / Quinases Ciclina-Dependentes / Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article